These experiments were done to determine the effect of @entity5217 and @entity6335 on the growth of @entity1 @entity150 (HTB-9) cells in vitro. Cell growth was assayed by cell counts, protein accumulation, and @entity665 uptake. @entity5217 added at 75 and 150 microM for 48 hr reduced cell proliferation. Dose-inhibition curves showed that @entity5217 added for 48 hr reduced cell growth at concentrations as low as 1 microM (IC50 = 73 microM) when growth was assayed in the absence of added serum. This microM-effect on cell growth was in agreement with the dose range in which @entity5217 decreased open probability of membrane KATP channels. Addition of @entity5217 for 48 hr also altered the distribution of cells within stages of the cell cycle as determined by flow cytometry using 10(-5) M @entity1603 . @entity5217 (100 microM) increased the percentage of cells in G0/G1 from 33.6% (vehicle control) to 38.3% (P < 0.05), and it reduced the percentage of cells in S phase from 38.3% to 30.6%. On the other hand, @entity6335 , which opens membrane KATP channels in HTB-9 cells, stimulated growth measured by protein accumulation, but it did not increase the cell number. We conclude that the @entity4136 receptor and the corresponding membrane KATP channel are involved in mechanisms controlling HTB-9 cell growth. However, KATP is not rate-limiting among the signaling mechanisms or molecular switches that regulate the cell cycle.

Membrane potassium channels and @entity1 XXXX cells: II. Growth properties.

@entity1 :: ('9606', 'Species') :: ['human'] @entity1603 :: ('MESH:D001973', 'Chemical') :: ['bromodeoxyuridine'] @entity6335 :: ('MESH:D003981', 'Chemical') :: ['diazoxide'] @entity5217 :: ('MESH:D005905', 'Chemical') :: ['Glibenclamide', 'glibenclamide'] @entity665 :: ('CHEBI:53526', 'Chemical') :: ['3H-thymidine'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder carcinoma'] @entity4136 :: ('CHEBI:26831', 'Chemical') :: ['sulfonylurea']
@entity150 :: (MESH:D001749,Disease) :: ['bladder tumor']
